Johnson & Johnson has announced a major breakthrough in mental health treatment. The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of ...

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...

If you’ve been diagnosed with major depressive disorder, seasonal affective depression or any other type of depression, your ...

The largest, most ethnically diverse, study of its kind has flagged hundreds of genetic variants that play a role in ...

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

Johnson & Johnson JNJ announced that the FDA has approved its supplemental new drug application (sNDA), seeking approval for ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with ma ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...